Q1 FY27 standalone revenue rises 28.6%, but profit after tax falls 30.9%
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
For standalone results for the quarter ended 30 June 2026, revenue from operations was Rs 2,379.06 lakh versus Rs 1,850.04 lakh in the year-ago quarter, up 28.6%. Profit after tax fell 30.9% to Rs 39.42 lakh from Rs 57.02 lakh. EPS declined to Rs 0.15 from Rs 0.24, and the profit margin narrowed to 1.7% from 3.1%.
Higher sales are positive, but the profit fall and narrower margin could weigh on the stock and signal weak earnings conversion.
The filed figures for this quarter have not reached us in XBRL yet, so there is nothing to compute here; the read above is the AI's, from the document. The table appears the moment the figures land.